Literature DB >> 16542196

The phase 0 microdosing concept.

R Colin Garner1, Graham Lappin.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16542196      PMCID： PMC1885041          DOI： 10.1111/j.1365-2125.2006.02575.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography.

Authors:  E O. Aboagye; P M. Price; T Jones
Journal:  Drug Discov Today       Date:  2001-03-01       Impact factor: 7.851

2.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

Review 3.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality?

Authors:  David F Horrobin
Journal:  Nat Rev Drug Discov       Date:  2003-02       Impact factor: 84.694

Review 4.  Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.

Authors:  Graham Lappin; R Colin Garner
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

Review 5.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

6.  Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry.

Authors:  Graham Lappin; R Colin Garner
Journal:  Anal Bioanal Chem       Date:  2003-11-18       Impact factor: 4.142
  6 in total
  22 in total

Review 1.  The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies.

Authors:  Xiaodong Liu; Lee Jia
Journal:  Curr Drug Metab       Date:  2007-12       Impact factor: 3.731

2.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

Authors:  Oliver Jonas; Heather M Landry; Jason E Fuller; John T Santini; Jose Baselga; Robert I Tepper; Michael J Cima; Robert Langer
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

Review 3.  Quantifying exploratory low dose compounds in humans with AMS.

Authors:  Stephen R Dueker; Le T Vuong; Peter N Lohstroh; Jason A Giacomo; John S Vogel
Journal:  Adv Drug Deliv Rev       Date:  2010-10-31       Impact factor: 15.470

Review 4.  A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug.

Authors:  Ashish A Gawai; Faisal Shaikh; Mangesh Gadekar; Nitin Deokar; Shivanand Kolhe; K R Biyani
Journal:  Turk J Pharm Sci       Date:  2017-04-15

5.  Preparation and evaluation of a 68Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate.

Authors:  Irina Velikyan; Örjan Lindhe
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

6.  Carbon isotopes profiles of human whole blood, plasma, red blood cells, urine and feces for biological/biomedical 14C-accelerator mass spectrometry applications.

Authors:  Seung-Hyun Kim; Jennifer C Chuang; Peter B Kelly; Andrew J Clifford
Journal:  Anal Chem       Date:  2011-03-31       Impact factor: 6.986

7.  Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats.

Authors:  Michael A Malfatti; Victoria Lao; Courtney L Ramos; Voon S Ong; Kenneth W Turteltaub
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

8.  Calculating radiation exposures during use of (14)C-labeled nutrients, food components, and biopharmaceuticals to quantify metabolic behavior in humans.

Authors:  Seung-Hyun Kim; Peter B Kelly; Andrew J Clifford
Journal:  J Agric Food Chem       Date:  2010-04-28       Impact factor: 5.279

9.  Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry.

Authors:  Jinsong Ni; Hui Ouyang; Mauro Aiello; Carmai Seto; Lisa Borbridge; Takeo Sakuma; Robert Ellis; Devin Welty; Andrew Acheampong
Journal:  Pharm Res       Date:  2008-02-26       Impact factor: 4.200

10.  Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Authors:  Irina Velikyan; Anders Wennborg; Joachim Feldwisch; Henrik Lindman; Jörgen Carlsson; Jens Sörensen
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.